Media Center
Publicaciones
Phase 2 of Pro-Autophagic Drug ABTL0812 in Combination With First-Line Paclitaxel and Carboplatin in IIIb/IV Squamous NSCLC
IASLC, 2020 World Conference on Lung Cancer, Singapore, January 2021
Phase 2 of ABTL0812, a pro-autophagic drug, in combination with paclitaxel and carboplatin as first-line treatment in advanced/recurrent endometrial cancer
ESMO 2020 - Abstract 2727
C. Domènech , J. Alfon, I. Ray-Coquard, A. Oaknin
The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.
Posted online: 13 May 2020
https://doi.org/10.1080/15548627.2020.1761651
Phase 1 of ABTL0812, a proautophagic drug, in combination with paclitaxel and carboplatin at first-line in advanced endometrial cancer and squamous cell lung carcinoma
Meeting: 2019 ASCO Annual Meeting - Abstract No: 3089 - Poster Board Number: Poster Session (Board 81) - Citation: J Clin Oncol 37, 2019 (suppl; abstr 3089)
Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.
Published: Gynecol Oncol. 2019 Mar 7
S0090-8258(19)30150-7
ABTL0812, a novel phase-2 clinical stage pro-autophagic anti-cancer compound with potential clinical activity in cholangiocarcinoma
2019 Cholangiocarcinoma Foundation Annual Conference
Preclinical and clinical development of ABTL0812: a new antitumoral drug that induces autophagy-mediated cancer cell death by upregulating TRIB3 pseudokinase and impairing of Akt/mTORC1 axis.
1st Oncobell Symposium. Mechanisms of Cancer and New Therapeutic Strategies. Barcelona 2018.
Exploring pharmacokinetic/pharmacodynamic considerations in translational oncology; from preclinical development to Phase II operations
Outsourcing in Clinical Trials. Barcelona 2018.
Preclinical and clinical development of ABTL0812: a new antitumoral drug that induces autophagy-mediated cancer cell death by upregulating TRIB3 pseudokinase and impairing of Akt/mTORC1 axis.
16th International Congress ASEICA, 2018.
Development of TRIB3 as a novel preclinical and clinical pharmacodynamic biomarker for ABTL0812
J Clin Oncol 36, 2018 (suppl; abstr e14556).
The new antitumoral drug ABTL0812 induces autophagic cell death by a dual mechanism: inhibition of Akt/mTORC1 axis and impairing desaturase-1 activity.
Transautophagy, Copenhaguen 2017.
Determination of recommended phase II dose of ABTL0812, a novel regulator of Akt/mTOR axis, by pharmacokinetic-pharmacodynamic modelling
Published: 11 Oct. 2016
Ann Oncol (2016) 27 (suppl_6): 378P
The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase
Published: 15 May 2016
10.1158/1078-0432.CCR-15-1808
ÚLTIMAS NOTICIAS
Notas de Prensa
La farmacéutica china SciClone se incorpora al capital de AbilityPharma con un compromiso de inversión de tres millones de dólares + infoNotas de Prensa
El fármaco antitumoral ABTL0812 obtiene resultados prometedores contra el neuroblastoma + infoNotas de Prensa
AbilityPharma recibe la aprobación de la FDA y la AEMPS para empezar en España y EEUU el ensayo clínico de su molécula contra el cáncer de páncreas + infoNotas de Prensa
AbilityPharma recibe una subvención de 1,6 millones de euros de la FDA y abre una campaña de inversión colectiva en Capital Cell + infoNotas de Prensa
ABILITYPHARMA PRESENTA LOS RESULTADOS DE UN NUEVO TRATAMIENTO DE PRIMERA LÍNEA PARA CÁNCER DE ENDOMETRIO + infoNotas de Prensa
AbilityPharma publica la caracterización completa del mecanismo de acción de ABTL0812, un inductor de autofagia citotóxica en células cancerígenas en fase clínica II, en la revista Autophagy + infoNotas de Prensa
AbilityPharma obtiene 5 millones de euros del Programa Piloto Horizon Europe EIC Accelerator para realizar un ensayo clínico de fase 2b con ABTL0812 en pacientes con cáncer de páncreas avanzado + infoNotas de Prensa
AbilityPharma capta 3,5 millones de € en una ronda de financiación para finalizar el ensayo fase 2 oncológico actual y licenciar ABTL0812 a una farmacéutica internacional + infoNotas de Prensa
Ability Pharmaceuticals anuncia la presentación de los primeros resultados de ABTL0812 como a terapia de primera línea en pacientes con cáncer de endometrio o de pulmón en el Annual Meeting ASCO 2019 + info